Online citations, reference lists, and bibliographies.
← Back to Search

Is Pleurectomy And Decortication Superior To Palliative Care In The Treatment Of Malignant Pleural Mesothelioma?

I. Zahid, S. Sharif, T. Routledge, M. Scarci
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether pleurectomy/decortication (P/D) is superior to palliative care in the treatment of patients with malignant pleural mesothelioma (MPM). Overall 80 papers were found using the reported search, of which 11 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results are tabulated. We conclude that P/D may lead to superior survival rates but at the expense of higher morbidity rates to palliative treatment. Six studies reported patient outcomes after use of radical P/D to treat patients with MPM. Radical P/D leads to a higher median survival than supportive care (14.5 vs. 4.5 months) and non-radical decortication (15.3 vs. 7.1 months, P < 0.000). However, radical P/D had a complication rate of 30%, hospital stay of 12 days with an operative mortality rate of 9.1%. One-year survival rate was 65% but this fell to 0-24% at three years. Three studies highlighted the use of palliative chemotherapy to manage patients with MPM. Median survival (14 vs. 10 months) was higher in patients who received chemotherapy early compared to those on a delayed protocol. Early chemotherapy had a longer time to disease progression (25 vs. 11 weeks, P = 0.1) and greater one-year survival (66% vs. 36%) than the delayed group. Active symptom control (ASC) alone had lower symptom control rates than the combination of ASC plus MVP (mitomycin+vinblastine+cisplatin) (7% vs. 11%, P = 0.0017) and ASC plus vinorelbine (4% vs. 7%, P = 0.047). Three studies reported results of palliative surgery in patients with known MPM. Median survival period was 213 days with a 30-day mortality rate of 7.8%. Survival rates reduced from 70.6% at three months to 25.5% at one-year post-surgery. Prolonged air-leak and postoperative empyema complicated 9.8% and 4% of patients, respectively. P/D is a morbid operation that is associated with significant perioperative mortality and complication rates. Although a number of retrospective studies have shown a small benefit in survival with P/D, the heavily documented similarity in patient outcomes between P/D and extrapleural pneumonectomy along with the results of the Mesothelioma and Radical Surgery trial, should induce the surgical community to consider the use of P/D only in patients with malignant mesothelioma enrolled in prospective trials.
This paper references
10.1016/J.LUNGCAN.2004.11.003
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
10.1016/S1569-9293(03)00191-9
Towards evidence-based medicine in cardiothoracic surgery: best BETS.
J. Dunning (2003)
10.1016/S1010-7940(01)00995-2
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
A. Martin-Ucar (2001)
10.1002/JSO.1143
Survival after conservative (palliative) management of pleural malignant mesothelioma
N. Merritt (2001)
10.1510/icvts.2008.197160
Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis?
Vivek Srivastava (2009)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1510/ICVTS.2007.166322
Radical surgery for malignant pleural mesothelioma: results and prognosis.
M. Okada (2008)
10.1016/S1010-7940(02)00735-2
The management of malignant pleural mesothelioma.
G. Maggi (2003)
10.1093/ANNONC/MDJ073
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
10.1016/j.ejcts.2009.08.016
Surgery for mesothelioma: MARS landing and future missions.
T. Treasure (2010)
10.1016/j.ejcts.2008.06.010
Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy.
A. Nakas (2008)
10.1016/j.ejcts.2009.07.032
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
H. Luckraz (2010)
10.1016/J.ATHORACSUR.2007.06.066
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)



This paper is referenced by
Malign plevral mezotelyoma hastalarinda destek tedavisi ve plöredezin karşilaştirilmasi Comparison of supportive treatment and pleurodesis in patients with malignant pleural mesothelioma
Özlem Abakay (2012)
10.1186/1471-2407-12-615
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)
U. Petrausch (2012)
10.1007/978-3-319-28761-4_21
Modern Surgical Techniques in Malignant Pleural Mesothelioma
Y. Kahya (2016)
10.5606/TGKDC.DERGISI.2016.11798
Can hyperthermic intrathoracic perfusion chemotherapy added to lung sparing surgery be the solution for malignant pleural mesothelioma
A. Işık (2016)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology
R. Martins (2012)
10.21037/tlcr.2017.05.02
Immunotherapy for malignant pleural mesothelioma: current status and future directions.
J. Dozier (2017)
10.1007/s13665-012-0012-2
Management of malignant pleural effusions
D. Hsia (2012)
10.5798/DICLEMEDJ.0921.2012.04.0191
Malign plevral mezotelyoma hastalarında destek tedavisi ve plöredezin karşılaştırılması
Abdullah Cetin Tanrıkulu (2012)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.2995/JACSURG.25.687
胸膜中皮腫の外科治療を巡る諸問題 : EPPかP/Dか
坪田 紀明 (2011)
The hedgehog pathway on malignant mesothelioma
C. Lim (2015)
10.1517/14712598.2015.1116515
Tremelimumab for the treatment of malignant mesothelioma
A. Guazzelli (2015)
10.1186/s13019-020-01158-3
Development of an effective method utilizing fibrin glue to repair pleural defects in an ex-vivo pig model
Nobuyuki Kondo (2020)
10.6004/JNCCN.2016.0087
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
D. Ettinger (2016)
10.1007/s12055-017-0566-2
Immunotherapy for thoracic malignancies
J. Dozier (2017)
10.1093/icvts/ivs465
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
J. Lindenmann (2013)
10.5798/diclemedj.0921.2012.04.0191
Comparison of supportive treatment and pleurodesis in patients with malignant pleural mesothelioma
A. Abakay (2012)
10.3978/j.issn.1000-9604.2013.02.04
Safety and efficacy of trimodality therapy in patients undergoing extrapleural pneumonectomy.
Servet Boeluekbas (2013)
10.1016/j.lungcan.2013.04.019
Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.
S. Boeluekbas (2013)
10.2147/OTT.S100214
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma
Abdel-Ghani M. Azzouqa (2016)
Pulmonary Disease BoarD reView manual management of malignant Pleural effusions
D. Hsia (2015)
10.1093/BJACEACCP/MKU040
Malignant pleural mesothelioma and its management
M. Daunt (2015)
10.1634/theoncologist.2014-0122
Current issues in malignant pleural mesothelioma evaluation and management.
J. Ai (2014)
10.1097/JTO.0b013e31828353d7
Surgery in mesothelioma--where do we go after MARS?
B. Hiddinga (2013)
10.1155/2014/817203
Surgical Management of Malignant Pleural Mesothelioma: Impact of Surgery on Survival and Quality of Life—Relation to Chemotherapy, Radiotherapy, and Alternative Therapies
S. Papaspyros (2014)
Semantic Scholar Logo Some data provided by SemanticScholar